Clonal hematopoiesis (CH)dan expansion of blood cells derived from a single hematopoietic stem celldis a defining feature of hematologic cancers, but recently CH was also found to be a frequent consequence of aging. When aging-associated CH results from acquisition of a somatic mutation in a driver gene associated with leukemia, and this mutation is present at a variant allele frequency of at least 0.02 (2%) yet the patient does not meet World Health Organization diagnostic criteria for a hematologic neoplasm, this state is termed clonal hematopoiesis of indeterminate potential (CHIP). CHIP is present in approximately 10% to 15% of people older than 70 years and more than 30% by age 85 years and represents a precursor state for neoplasia akin to monoclonal gammopathy of undetermined significance. Recently, CHIP was unexpectedly found to be an important risk factor for cardiovascular events, with accumulating evidence supporting a mechanism of accelerated atherogenesis as a result of vascular inflammation driven by clonally derived monocytes/macrophages. Risk factors for CHIP include aging, male sex, cigarette smoking, and a common germline variant in the telomere-associated gene TERT. Clonal hematopoiesis can also occur after cytotoxic chemotherapy or radiotherapy for a solid tumor, after hematopoietic stem cell transplant, in the context of aplastic anemia, or after induction chemotherapy for acute leukemia; in each setting, CH has distinct clinical implications. This review summarizes recent studies of CH and CHIP and outlines challenges in clinical management of affected patients.
A s we age, a substantial proportion of us will develop an expanded "clone" of blood cells bearing a somatic mutation in a leukemia-associated driver gene such as DNMT3A or TET2 (for expansion of gene symbols, see http://www.genenames. org) yet will not fulfill any of the World Health Organization (WHO) diagnostic criteria for a hematologic malignancy. [1] [2] [3] Most people with such blood cell clones have an entirely normal complete blood cell count, or at most a slight elevation in the mean cell volume.
Such mutant marrowederived clones are common, present at a variant allele frequency (VAF; ie, mutation burden, proportional to the number of abnormal cells) of 2% or greater in more than 10% of the population aged 65 years and older. When defined using a 2% VAF cutoff value (because very small clones with <0.05% VAF are almost universal in middle age and beyond), these clones confer a 0.5% to 1% annual risk of developing a hematologic cancer, mostly myeloid neoplasms, in the same way that the small plasma cell clones defining monoclonal gammopathy of undetermined significance (MGUS) represent a risk factor for overt plasma cell neoplasms such as myeloma or that monoclonal B-cell lymphocytosis can subsequently lead to chronic lymphoid leukemia or non-Hodgkin lymphoma. 4, 5 In addition, and of far greater public health consequence, clonal hematopoiesis (CH) increases an individual's risk of experiencing a myocardial infarction or stroke and of dying from a cardiovascular event. 2, 6 Investigators are only just beginning to elucidate the mechanisms by which CH contributes to acute cardiovascular events. Compelling new evidence supports the concept that inflammatory proatherogenic interactions between circulating clonally derived cells and vascular endothelium accelerate vascular disease and increase the risk of atherosclerotic plaque rupture. 6, 7 In addition to aging-associated CH, CH can also occur in several other clinical settings, such as after aplastic anemia, hematopoietic stem cell transplant, or cytotoxic therapy for a nonmyeloid neoplasm (eg, adjuvant therapy for breast cancer). Clonal hematopoiesis is a neoplasia precursor state, similar to a colon polyp or atypical cellular changes in the breast, but it lacks an anatomical form and thus can be detected only by DNA sequencing. This review outlines the distinct states in which CH can be detected and the clinical implications in each setting. The PubMed and MEDLINE databases were searched for articles published from January 1, 2012, through March 1, 2018, using the following terms: clonal hematopoiesis, myeloid neoplasia, age-related clonal hematopoiesis, myelodysplastic syndromes, acute myeloid leukemia, and somatic mosaicism. Articles were considered for inclusion if they represented primary data or were review articles published in high-impact journals.
DISCOVERY OF CH IN THE GENERAL POPULATION
Although it has long been recognized that a small proportion of healthy individuals can be found transiently to have low levels of oncogenic genetic alterations in circulating blood cells, such as the BCR-ABL fusion that is associated with chronic myeloid leukemia, the discovery that CH is common in the general population is relatively recent. In 2012, Busque et al 8 observed that somatic TET2 mutations were present in 5% of 182 older women with acquired age-related skewing of hematopoiesis, defined by imbalanced expression of polymorphic X-linked genes, 1 copy of which normally is unexpressed in each cell in females due to lyonization (ie, chromosome condensation) during fetal life.
8 TET2 mutations are present in 15% to 25% of patients with myeloid neoplasms and were described as leukemia driver events in 2009, and such mutations had not previously been recognized in healthy persons without cancer. 9 Also in 2012, 2 groups analyzed genomic array data from more than 50,000 people and reported that acquired chromosome mosaicism, including aneuploidy and large segmental deletions, occurs in 2% to 3% of elderly persons, but is rare before age 50 years. 10, 11 Somatic mosaicism at the chromosome level in those series was associated with a 10-fold increased risk of developing a hematologic cancer, as well as reduced survival. Finally, in 2014, 3 independent groups of investigators analyzed DNA sequencing results from thousands of patients who had enrolled in large genome-wide association studies that had been conducted to assess genetic risk for nonhematologic diseases, such as schizophrenia or diabetes mellitus.
1-3 The 3 groups of investigators each noted that mutations in genes previously associated with the development of leukemia are common in older persons and that the frequency of these mutations increases with aging.
DEFINITION OF CHIP AND RISK FACTORS FOR DEVELOPMENT OF CHIP
In 2015, several colleagues and I proposed a new term to describe the presence of a clonal blood cell population associated with a leukemia driver mutation at a VAF of 2% or greater but in the absence of severe cytopenias or a WHO-defined disorder: CH of indeterminate potential (CHIP). 12 Although CHIP is not a hematologic disorder by itself, and in many cases this biological state has no detectable clinical consequences, CHIP is important to identify because it represents both a risk factor for evolution to various WHOdefined hematologic malignancies ( Figure 1 ) and a cardiovascular danger. Perhaps due to the intellectually satisfying parallel with the welldescribed hematologic malignancy precursor states of MGUS (described by Robert Kyle and Jan Waldenström more than 40 years ago 13, 14 ) and monoclonal B-cell lymphocytosis, 15 as well as the need to have a term to easily communicate with other investigators about a common and clinically consequential state, the hematology community quickly adopted the acronym CHIP. CHIP was featured in a front-page story in the New York Times in January 2018dthe first time the word hematopoiesis had appeared in the 167-year history of the Times. 16 
ARTICLE HIGHLIGHTS
d Clonal hematopoiesisdexpansion of genetically identical blood cells derived from a single hematopoietic stem celldis commonly observed in older persons.
d Clonal hematopoiesis is a risk factor for hematologic neoplasia, cardiovascular events, and overall mortality.
d Clonal hematopoiesis can also be observed in other settings, such as aplastic anemia, after therapy for a nonmyeloid neoplasm, after stem cell transplant, or after therapy for acute myeloid leukemia; clonal hematopoiesis has distinct implications in each of these settings.
d Clonal hematopoiesis cannot be treated directly, but clinical management includes monitoring for disease progression and attention to cardiovascular risk factors.
Despite widespread interest in CHIP among hematologists, oncologists, and cardiologists, there is not yet uniform consensus about the roster of specific mutations defining CHIP or whether 2% is the optimal VAF threshold to define this entity. [17] [18] [19] A recent Icelandic study demonstrated that agingassociated CH can occur even in the absence of mutations in recognized leukemic drivers, and other investigative groups have shown that development of small expanded clones below the proposed 2% VAF threshold may be nearly universal beyond age 50 years. 20, 21 It remains unclear whether these smaller clones confer malignancy and cardiovascular mortality risks as CHIP does.
Aging seems to be the principal risk factor for developing CHIP, leading some investigators to use the term age-related CH to describe CH in the elderly. Although the term age-related CH emphasizes the association between CH and aging, CHIP is not an inevitable consequence of aging and is occasionally seen in young people. Male sex and cigarette smoking are associated with a modestly increased risk of CHIP. 1, 22 A germline polymorphism in TERT, a gene encoding a component of the telomerase complex, is also associated with a higher likelihood of having CHIP, despite the absence of differences in telomere length between persons with wild-type and variant TERT. associated with a single driver mutation in the DNMT3A gene, DNMT3A R882H, the most common CHIPassociated mutation. At the time of CHIP (which was diagnosed retrospectively from archival samples), the patient had a normal blood cell count. Several years later, a cell in this DNMT3A mutant clone acquired a second mutationda loss of function mutation in the RUNX1 transcription factordand pancytopenia evolved and the patient met World Health Organization diagnostic criteria for MDS. After several more years, the patient developed leukocytosis and circulating blasts and a new internal tandem duplication mutation in FLT3 was discovered in a subclone.
example, detection of CH after chemotherapy or radiotherapy for a nonmyeloid neoplasm was discovered to increase the risk of therapy-related myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), especially if the emergent clones bear a TP53 or PPM1D mutation. [23] [24] [25] Clonal hematopoiesis at the time of autologous transplant for non-Hodgkin lymphoma is also associated with increased therapy-related MDS/AML, posttransplant cytopenias, and reduced overall survival; in a series of 401 patients, 10-year survival was 30.4% in the 29.9% of posttransplant patients with CH, compared with 60.9% survival in those without CH. 26 Furthermore, CH in older allogeneic hematopoietic stem cell transplant donors has been associated with poorer transplant outcomes and a risk of donor-derived leukemia, influencing donor choice in some transplant programs in favor of younger haploidentical donors and away from elderly siblings. 26, 27 Patients who develop aplastic anemia are at risk for clonal progression to paroxysmal nocturnal hemoglobinuria or to MDS/AML. A high-profile next-generation sequencing (NGS) analysis of the consequences of acquired clonal FIGURE 2. Clonal hematopoiesis (CH) occurs in distinct settings with differing implications. It is almost universal with aging; when CH is associated with a leukemia driver mutation present at a variant allele frequency of 2%, it is called CH of indeterminate potential (CHIP) and is a risk factor for development of a myeloid neoplasm and cardiovascular events. After therapy for a nonmyeloid neoplasm, CH is enriched for mutations in TP53, which are selected for by cytoreductive therapy that decreases the burden of TP53 wild-type clones. This type of CH is a strong risk factor for therapy-related myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML). Also, CH can arise during the course of aplastic anemia and can persist for many years. There seem to be 2 general classes of CH occurring in the context of aplastic anemia: a more benign type associated with mutations in PIGA (associated with paroxysmal nocturnal hemoglobinuria), BCOR, or BCORL1, and a more dangerous type with mutations in other genes; the latter is associated with poorer response to immunosuppressive therapy and a greater risk of evolution to MDS and AML. After initial therapy for AML, minimal residual disease (MRD) is defined by CH; CH with mutations in DNMT3A, TET2, or ASXL1 confers a lower relapse risk than MRD associated with AML-associated genes such as FLT3, KRAS, or NPMA1.
mutations in 439 patients with aplastic anemia found that patients with somatic mutations in PIGA (which causes paroxysmal nocturnal hemoglobinuria), BCOR, or BCORL1 had a high likelihood of responding to immunosuppressive therapy and better overall outcomes than those with the CHIP-associated mutations DNMT3A or ASXL1. 28 In this series, the development of CH, although often interpreted as an ominous sign, was usually not associated with progression to MDS/AML.
After initial therapy for leukemia, the presence of residual clonal cells is a marker of the remaining tumor burden, and also a strong prognostic marker independent of other clinical and pathologic variables. Minimal residual disease (MRD) (also known as measureable residual disease) testing for the persistence of such cells is now a routine clinical practice. For example, in acute lymphoid leukemia, MRD after initial therapy is usually measured by cell-based flow cytometry, whereas for leukemias associated with an aberrant transcript such as acute promyelocytic leukemia or chronic myeloid leukemia, confirming remission and monitoring for relapse involves following patients serially with reverse transcriptase polymerase chain reaction assays. Detection of MRD may influence clinicians' choice of postremission therapy.
However, MRD testing is not yet routine for AML, and MRD in AML may be more complex in part because of the high frequency of CHIP in older persons. 29 In Dutch-Belgian and Swiss cooperative group studies of AML, more than half of patients still had detectable clonal mutations by NGS after initial induction chemotherapy, and these mutations were a risk factor for relapse. 30 In contrast, mutations in DNMT3A, ASXL1, or TET2 were associated with a lower relapse risk at a median follow-up of 40 months, similar to the risk of MRD-negative patients, probably because these CH-initiating mutations lack leukemic potential by themselves and require subsequent acquisition of an additional new mutation to result in AML. 31 
CLINICAL IMPLICATIONS OF CHIP
At the same time as these epidemiologic observations, increasingly easy access in the clinic to NGS assays has led to identification of a new and growing population of patients who are aware that they have CHIP. 32 Hematologists and nonhematologists, including primary care physicians, are now commonly ordering NGS panels to evaluate minor blood cell count abnormalities that could represent an early sign of MDS or another neoplasm. These changes include an elevated mean cell volume, minor alteration in the leukocyte differential cell count (eg, relative monocytosis), or mild thrombocytopenia or neutropenia that in the past might have simply been observed with serial complete blood cell counts. Discussion of how to assess whether a detected mutation is the cause of a cytopenia is beyond the scope of this review, but studies have confirmed that cytopenias accompanied by clonal mutationsdso-called clonal cytopenia(s) of undetermined significancedhave a much higher risk of progression to overt MDS/AML and poorer outcome than cytopenias without clonal mutations, known as idiopathic cytopenias of uncertain significance. 33, 34 Given the high prevalence of CH in older people, this use (possibly misuse) of NGS assays has led to a growing population of "worried well" patients followed in hematologyoncology clinics. The population with CHIP also includes patients with nonmyeloid neoplasms in which leukemia-associated driver mutations are discovered during a marrow evaluation for the other neoplasm that includes an NGS panel with myeloid-associated genes on it. Institutions that routinely assess paired blood and tumor samples to evaluate patients with newly diagnosed nonhematologic neoplasms have begun to create dedicated clinics to help care for patients identified as having mutations restricted to the blood compartment and not in the tumor. 35 Discovery of CHIP and uncertainty about future evolution may cause anxiety for patients, akin to that described in some men with early prostate cancer who are approached with a strategy of active surveillance and "watchful waiting." 16, 36 It may be helpful to clarify for patients with CHIP that they do not have a disease per se but instead a common condition that is a risk factor for disease.
CLINICAL CONSIDERATIONS FOR PATIENTS WITH CH
Management of patients with CHIP is challenging due to the absence of prospective trials. However, the current lack of clinical trial data does not eliminate the need to make clinical choices.
The cardiovascular risk associated with a hematopoietic clone with a greater than 2% VAF driver mutation is of a similar magnitude to the risk incurred by uncontrolled hyperlipidemia or cigarette smoking. 2, 6 In an analysis of 4 case-control studies that included 4726 participants with coronary heart disease and 3529 controls, the hazard ratio for myocardial infarction was 1.9 times (95% CI, 1.4-2.7 times) greater in those with CHIP as in those without mutations in the 2 prospective cohorts, whereas in the 2 retrospective case-control cohorts, the hazard ratio for early myocardial infarction associated with CHIP was even greater (4.0; 95% CI, 2.4-6.7). 6 Because we do not yet know how to diminish the cardiovascular event risk associated with CHIP (discussed further later herein), it should be a priority to minimize any other cardiovascular risk factors that may be present in the individual patient. Encouraging patients to quit smoking and optimally controlling hypertension and diabetes mellitus are important first steps for patients who have these obvious risk factors.
Although we do not yet know whether aspirin or cholesterol-lowering statins reduce vascular morbidity or mortality in patients with CHIP, given the low risk of these interventions, they seem reasonable to discuss with patients with CHIP. However, there are no data yet showing benefit specifically in the population with CHIP. Patients with CHIP should also consider following American Heart Association lifestyle guidelines, including reduction of dietary intake of saturated fats and trans-fatty acids to less than 7% of total calories, increased intake of viscous fiber and plant stanol esters/ sterols, and regular physical exercise. 37, 38 Finally, given the major cardiovascular risk associated with CHIP, it seems that the goal for lipid-lowering therapy in patients with CHIP should be that recommended by the American Heart Association, American College of Cardiology, European Society of Cardiology, and other organizations for secondary cardiac prevention, rather than primary prevention, ie, achieving low-density lipoprotein cholesterol levels less than 100 mg/dL (to convert to mmol/L, multiply by 0.0259). 39 
INTERACTIONS BETWEEN CLONALLY DERIVED CELLS AND THE ENDOTHELIUM
In a murine model using atherosclerosis-prone, low-density lipoprotein receptoredeficient (Ldlr e/e ) mice, TET2-deficient macrophages exhibited an increase in NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome-mediated cytokine and chemokine secretion, including interleukin-6 and interleukin-1b. 7, 40 Interleukin-1b upregulates expression of P-selectin in vascular endothelial cells, which recruits more monocytes (clonal and nonclonal) to preexisting fatty plaques. This model suggests that inhibition of the inflammasome-mediated signaling cascade might lower the risk of inflammation-associated plaque progression and rupture. 41 Of note, activation of the NLRP3 inflammasome in the context of the marrow microenvironment is also a hallmark of MDS. 42 The MDS hematopoietic stem and progenitor cells expressing inflammasome proteins and activated NLRP3 complexes may trigger pyroptotic cell death, increasing levels of reactive oxygen species and activating nuclear beta-catenin, thereby contributing to cytologic dysplasia and ineffective hematopoiesis. 43 Currently available inhibitors of interleukin-1b include the fusion proteins canakinumab, rilonacept, and anakinra; these agents deserve study in the settings of CH and MDS. 44 In a placebo-controlled clinical trial of canakinumab in 10,061 patients who had previously had a myocardial infarction and an elevated high-sensitivity C-reactive protein level (2 mg/L [to convert to nmol/L, multiply by 9.524]), use of the highest studied dose of canakinumab reduced the risk of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death (hazard ratio vs. placebo, 0.83; 95% CI, 0.73-0.95; P¼.005) without lowering lipid levels. 45 This trial began in 2011 before the discovery of CHIP, but DNA sequencing of pretreatment samples is ongoing to assess whether the patients who benefitted most from the intervention are those with CH. Vitamin C is also worth studying in this setting because recent high-quality data suggest that vitamin C restores some aspects of TET2 function, and TET2 mutations are the second-most common CHIP-associated variant. 46 
REDUCING OR ELIMINATING THE EXPANDED CLONAL POPULATION
Ideally, in addition to mitigating the vascular consequences in the short-term, therapy of CHIP would eliminate the source clonal population and restore fully normal, polyclonal hematopoiesis. This would be especially important in CH detected after previous treatment with chemotherapy or radiotherapy of a nonmyeloid neoplasm, where the risk of therapy-related MDS/AML is substantial if CHIP is present (>25%). However, there are 2 major barriers to achieving this goal.
The first difficulty is that cytoreduction of a dominant clone may actually worsen cytopenias due to marrow failure, at least transiently, or allow other mutant clones to emerge. This is especially likely in elderly patients with oligoclonal hematopoiesis, limited marrow reserve, and a background of many somatic mutations. As the old proverb says, "Better the devil you know than the devil you don't." When lenalidomide was first used for lower-risk MDS with del(5q), for example, there was concern that suppression of the more "benign" del(5q) clone would permit outgrowth of a highly malignant TP53-mutant clone that was being kept in check by the del(5q) clone, and TP53-mutant clonal emergence remains a major mechanism of disease progression in patients receiving lenalidomide therapy, although a randomized placebo-controlled trial of lenalidomide did not show an increased leukemia risk. [47] [48] [49] The second challenge is that unlike plasma cell disorders or lymphoid malignancies for which a broad range of highly active cytoreductive drugs are now available, currently available drug therapies that alter the natural history of MDS are limited, so there is not a long list of candidates to try to reduce CHIP. 50 Four drugs (gemtuzumab ozogamicin, midostaurin, enasidenib, CPX351) were approved by the US Food and Drug Administration (FDA) for AML in 2017, but there have been no new drug approvals in MDS since 2006, and the only approved agents in addition to lenalidomide for del(5q) patients are the DNA methyltransferase inhibitors decitabine and azacitidine. Even when a hematologic and cytogenetic remission occurs with 1 of these 3 agents, mutant HSPCs persist at a low level and can serve as a nidus for relapse, and only the graft-versus-leukemia effect of allogeneic transplant can entirely eliminate such abnormal clones. 51, 52 In the setting of MGUS and smoldering myeloma, clinical trials of daratumumab-based regimens are ongoing to try to prevent evolution of the precursor state to overt malignancy, 53 but it is difficult to envision how to conduct such trials in MDS with the available, admittedly mediocre, agents.
Clinical trials of low-dose decitabine and azacitidine in MDS (ie, using schedules shorter than the current FDA-approved 5-and 7-day administration schedules, respectively) have shown that an abbreviated-schedule approach is well tolerated and is associated with improved hematopoiesis and reduction of the total burden of clonal cells, although abnormal cells persist. 54 Although it is unclear whether the risk of prolonged nucleoside analogue therapy is acceptable in patients with CHIP, it may at least be possible to delay the onset of MDS/ AML with 1 of these agents by achieving a several log reduction in the burden of clonal cells. This approach should be reserved for clinical trials but is especially attractive in patients with evidence of CH after treatment for a nonmyeloid malignancy. Such patients need to be followed closely not only for early detection of recurrence of their primary malignancy but also for emergence of cytopenias. However, development of new treatments is more critical than enhanced observation.
In the meantime, we can take steps to avoid transferring CH from one person to another. This means screening older donors and prohibiting persons with CHIP from serving as allogeneic transplant donors, unless no other alternative donor is available (and perhaps even then). The growing use of and success with haploidentical transplant even in older patients means that an elderly sibling is rarely the only potential donor. 55 
CONCLUSION
Clonal hematopoiesis is increasingly detected in patients with normal blood cell counts or mild blood cell count abnormalities. Mitigating cardiovascular risk factors is a priority for these patients. Conducting clinical trials of novel approaches to both reducing inflammasomemediated acceleration of atherogenesis and cytoreducing or eliminating clonal cells in the blood and marrow should be priorities for the hematology community. Because CHIP is a common risk factor for hematologic and cardiovascular adverse outcomes, consensus recommendations from a joint panel convened by the American Society of Hematology and American College of Cardiology or American Heart Association would be welcome. 
